FDA approves Zelsuvmi for molluscum contagiosum

Topical Zelsuvmi has been approved by the FDA for use in patients aged 1 year and older with molluscum contagiosum, Ligand Pharmaceuticals announced in a press release.
A topical antiviral gel, Zelsuvmi (berdazimer gel 10.3%) releases nitric oxide upon application and has an antimicrobial effect. It is the first prescription treatment indicated for the viral skin infection that mostly affects children.
“The approval of Zelsuvmi is a breakthrough, marking the first time that clinicians can treat molluscum with an efficacious topical prescription medication that is applied by the patient or

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.